Yun Wang , Zhi-jian Liang , Robert Peter Gale , Hua-ze Liao , Jun Ma , Tie-jun Gong , Ying-qi Shao , Yang Liang
{"title":"慢性髓性白血病：生物学与治疗","authors":"Yun Wang , Zhi-jian Liang , Robert Peter Gale , Hua-ze Liao , Jun Ma , Tie-jun Gong , Ying-qi Shao , Yang Liang","doi":"10.1016/j.blre.2024.101196","DOIUrl":null,"url":null,"abstract":"<div><p>Chronic myeloid leukaemia (CML) is caused by <em>BCR::ABL1</em>. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the <em>optimal</em> therapy goal. Which TKI is the <em>best</em> initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101196"},"PeriodicalIF":6.9000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic myeloid leukaemia: Biology and therapy\",\"authors\":\"Yun Wang , Zhi-jian Liang , Robert Peter Gale , Hua-ze Liao , Jun Ma , Tie-jun Gong , Ying-qi Shao , Yang Liang\",\"doi\":\"10.1016/j.blre.2024.101196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Chronic myeloid leukaemia (CML) is caused by <em>BCR::ABL1</em>. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the <em>optimal</em> therapy goal. Which TKI is the <em>best</em> initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.</p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":\"65 \",\"pages\":\"Article 101196\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X24000298\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X24000298","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.
期刊介绍：
Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
